Biothera Drug Synergistic with Avastin® Against Cancer, Study Finds
News Mar 12, 2008
Biothera’s Imprime PGG™ increased the effectiveness of Avastin? (bevacizumab), a monoclonal antibody approved for the treatment of metastatic colorectal, breast and non-small cell lung cancer, according to a new preclinical study published in the current issue of Clinical Cancer Research.
Researchers in the Tumor Immunobiology Program of the James Graham Brown Cancer Center, University of Louisville, Kentucky, studied the synergistic effects of Imprime PGG in combination with Avastin in a xenograft mouse model where human ovarian cancer cells were implanted into the mice.
In the treatment group receiving both Imprime PGG and Avastin, 86% of the mice survived 100 days compared with only 43% in the group receiving Avastin alone.
“Our study is the first to demonstrate that Avastin, an anti-angiogenic agent, co-administered with Imprime PGG, an agent that enhances innate immune effector cell function, results in synergistic anti-tumor effects,” said Carolina Salvador, M.D., a clinical instructor at the James Graham Brown Cancer Center. “This type of combination strategy has significant clinical implications and deserves further investigation.”
“These results are consistent with our previous research with Imprime PGG and various monoclonal antibodies in numerous cancer indications,” said Daniel K. Conners, president of Biothera’s Pharmaceutical Group. “We are now working to demonstrate the safety and efficacy of these novel cancer therapies in the clinic.”
Biothera is currently conducting a clinical trial with metastatic colorectal cancer patients receiving a combination therapy of Imprime PGG, Erbitux® (cetuximab), a monoclonal antibody from ImClone Systems, and Irinotecan, a chemotherapy drug from Pfizer.
The results of the trial are expected later in 2008. The company also plans to initiate a clinical study in lung cancer patients this year using a combination of Imprime PGG, Avastin and two chemotherapy drugs.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE
Chemists Develop Method to Synthesize Drugs From Renewable PrecursorsNews
Researchers have developed a new approach to the synthesis of benzofurans from cheap raw materials.READ MORE